Publication Date
| In 2025 | 0 |
| Since 2024 | 0 |
| Since 2021 (last 5 years) | 0 |
| Since 2016 (last 10 years) | 0 |
| Since 2006 (last 20 years) | 2 |
Descriptor
| Autism | 2 |
| Children | 2 |
| Comparative Analysis | 2 |
| Hyperactivity | 2 |
| Outcomes of Treatment | 2 |
| Pervasive Developmental… | 2 |
| Adolescents | 1 |
| Attention Deficit Disorders | 1 |
| Behavior Problems | 1 |
| Correlation | 1 |
| Drug Therapy | 1 |
| More ▼ | |
Author
| Aman, Michael G. | 1 |
| Arnold, L. Eugene | 1 |
| Ashwood, Paul | 1 |
| Bent, Stephen | 1 |
| Bertoglio, Kiah | 1 |
| Bostrom, Alan | 1 |
| Cook, Amelia M. | 1 |
| Hall, Kristy L. | 1 |
| Hendren, Robert L. | 1 |
| Ramadan, Yaser | 1 |
| Thompson, Susan | 1 |
| More ▼ | |
Publication Type
| Journal Articles | 2 |
| Reports - Research | 2 |
Education Level
Audience
Location
Laws, Policies, & Programs
Assessments and Surveys
| Aberrant Behavior Checklist | 2 |
What Works Clearinghouse Rating
Peer reviewed
Direct linkBent, Stephen; Bertoglio, Kiah; Ashwood, Paul; Bostrom, Alan; Hendren, Robert L. – Journal of Autism and Developmental Disorders, 2011
We conducted a pilot randomized controlled trial to determine the feasibility and initial safety and efficacy of omega-3 fatty acids (1.3 g/day) for the treatment of hyperactivity in 27 children ages 3-8 with autism spectrum disorder (ASD). After 12 weeks, hyperactivity, as measured by the Aberrant Behavior Checklist, improved 2.7 (plus or minus…
Descriptors: Autism, Hyperactivity, Food, Pervasive Developmental Disorders
Atomoxetine for Hyperactivity in Autism Spectrum Disorders: Placebo-Controlled Crossover Pilot Trial
Arnold, L. Eugene; Aman, Michael G.; Cook, Amelia M.; Witwer, Andrea N.; Hall, Kristy L.; Thompson, Susan; Ramadan, Yaser – Journal of the American Academy of Child and Adolescent Psychiatry, 2006
Objective: To explore placebo-controlled efficacy and safety of atomoxetine (ATX) for attention-deficit/hyperactivity disorder (ADHD) symptoms in children with autism spectrum disorders (ASD). Method: Children ages 5 to 15 with ASD and prominent ADHD symptoms were randomly assigned to order in a crossover of clinically titrated ATX and placebo, 6…
Descriptors: Hyperactivity, Autism, Drug Therapy, Attention Deficit Disorders
